Treats heartburn and other symptoms associated GERD. ANDA 213486, held by Graviti Pharms. Esomeprazole Magnesium.
As of Nov 15, 2026, ANDA 213486 (Esomeprazole Magnesium), held by Graviti Pharms, was first approved by FDA on Mar 19, 2021, with 3 approved supplements and 0 published complete response letters.
Esomeprazole is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2021 | Original application | Approved | None posted |
| Esomeprazole MagnesiumEQ 20MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| Esomeprazole MagnesiumEQ 40MG BASE · capsule, delayed rel pellets;oral | Esomeprazole Magnesium | Rx |
| Jan 10, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 10, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 10, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 19, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters